JACC. Clinical electrophysiology · 2026
Incidence and Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy in Light Chain Cardiac Amyloidosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moulin Thibaut, Zaroui Amira, Ramoul Khaled, Rouffiac Ségolène, Kharoubi Mounira, Djouadi Kamila, Guendouz Soulef, Elbaz Nathalie, Ouazana Victoria, Labbé Jean-Philippe, Galat Arnault, Gounot Romain, Belhadj Karim, Lemonnier François, Dhanjal Tarvinder S, Le Corvoisier Philippe, Audureau Etienne, Teiger Emmanuel, Oghina Silvia, Damy Thibaud, Lellouche Nicolas
Аннотация
BACKGROUND: Sudden cardiac death represents a common mode of death in patients with light chain cardiac amyloidosis (AL CA). However, data evaluating the role of implantable cardioverter defibrillator (ICD) in these patients are scarce.
OBJECTIVES: This study aimed to describe the incidence and identify factors associated with appropriate ICD therapies in AL CA patients.
METHODS: This was a retrospective, single referral center study including all AL CA patients implanted with ICDs between November 2014 and May 2024. The primary endpoint was the first appropriate ICD therapy (shock or antitachycardia pacing).
RESULTS: A total of 150 patients (mean age 63.4 ± 9.2 years, 65.3% male) were included, all with primary prevention ICDs. Over a median follow-up period of 16.8 months (Q1-Q3: 5.4-56.5 months), 27 (18.0%) patients received at least 1 appropriate ICD therapy (1-year cumulative incidence: 11.6%; 95% CI: 7.4%-18.2%; 5-year cumulative incidence: 19.5%; 95% CI: 13.4%-28.4%). In multivariate analysis, impaired left ventricular (LV) global longitudinal strain was independently associated with a higher risk of appropriate ICD therapy (optimal cutoff -9.5%; adjusted subdistribution HR: 5.33; 95% CI: 1.99-14.26; P = 0.0009).
CONCLUSIONS: AL CA patients implanted with prophylactic ICDs experience high rates of appropriate therapies. Assessment of LV involvement with LV global longitudinal strain might improve risk stratification for ventricular arrhythmias. Further studies are needed to assess the impact of ICD on overall survival in this population.
OBJECTIVES: This study aimed to describe the incidence and identify factors associated with appropriate ICD therapies in AL CA patients.
METHODS: This was a retrospective, single referral center study including all AL CA patients implanted with ICDs between November 2014 and May 2024. The primary endpoint was the first appropriate ICD therapy (shock or antitachycardia pacing).
RESULTS: A total of 150 patients (mean age 63.4 ± 9.2 years, 65.3% male) were included, all with primary prevention ICDs. Over a median follow-up period of 16.8 months (Q1-Q3: 5.4-56.5 months), 27 (18.0%) patients received at least 1 appropriate ICD therapy (1-year cumulative incidence: 11.6%; 95% CI: 7.4%-18.2%; 5-year cumulative incidence: 19.5%; 95% CI: 13.4%-28.4%). In multivariate analysis, impaired left ventricular (LV) global longitudinal strain was independently associated with a higher risk of appropriate ICD therapy (optimal cutoff -9.5%; adjusted subdistribution HR: 5.33; 95% CI: 1.99-14.26; P = 0.0009).
CONCLUSIONS: AL CA patients implanted with prophylactic ICDs experience high rates of appropriate therapies. Assessment of LV involvement with LV global longitudinal strain might improve risk stratification for ventricular arrhythmias. Further studies are needed to assess the impact of ICD on overall survival in this population.